Skip to main content
NXL
NASDAQ Industrial Applications And Services

Nexalin Shareholders Greenlight Reverse Split and Equity Plan, but Block Preferred Stock and Officer Exculpation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.358
Mkt Cap
$7.88M
52W Low
$0.305
52W High
$2
52W Position info
17% above low
Off High info
82% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

NXL sits 17% above its 52-week low of $0.305 on light trading volume (0.1× avg).

Summary

Nexalin Technology shareholders approved a reverse stock split and a new equity incentive plan, but rejected preferred stock authorization and officer exculpation. The reverse split gives the board a tool to address Nasdaq's minimum bid price deficiency.


Key Events · Corporate Governance and Compliance · NXL

  • Reverse Stock Split Approved

    Shareholders approved a reverse split at a ratio between 1-for-2 and 1-for-100, with an aggregate cap of 1-for-250, at the board's discretion. This provides a mechanism to raise the stock price above Nasdaq's $1.00 minimum bid requirement.

  • 2026 Equity Incentive Plan Adopted

    The new equity plan was approved with 8,248,630 votes for, adding potential future dilution to fund compensation.

  • Preferred Stock Authorization Rejected

    A proposal to authorize 10 million shares of preferred stock failed (7,863,517 for, 1,208,690 against), limiting the board's ability to raise capital or create a poison pill.

  • Officer Exculpation Amendment Fails

    An amendment to limit officer liability was not approved, leaving directors and officers exposed to certain shareholder claims.


Analysis · NXL · Industrial Applications And Services

At its annual meeting, Nexalin Technology shareholders handed the board a critical tool by approving a reverse stock split at a ratio between 1-for-2 and 1-for-100, with an aggregate cap of 1-for-250, providing broad discretion to regain Nasdaq compliance. The 2026 Equity Incentive Plan also passed, introducing potential dilution. However, two other proposals failed: one to authorize 10 million preferred shares and another to provide officer exculpation, thereby limiting the board's capital-raising and liability-shielding options. The reverse split approval is especially significant given the company's ongoing delisting threat and going-concern warning; the board now has the authority to execute a split to lift the stock price above $1.00.

At the time of this filing, NXL was trading at $0.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $0.31 to $2.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXL - Latest Insights

NXL
Jul 27, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4508
Real-time Price: $0.358 info
Change: -$0.0928 (-21%) info
Market Cap: $7.88M info
NXL
Jul 10, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.4496
Real-time Price: $0.358 info
Change: -$0.0916 (-20%) info
Market Cap: $7.88M info
NXL
Jun 29, 2026, 5:30 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.3561
Real-time Price: $0.358 info
Change: +$0.0019 (+0.53%) info
Market Cap: $7.88M info
NXL
Jun 23, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3601
Real-time Price: $0.358 info
Change: -$0.0021 (-0.58%) info
Market Cap: $7.88M info
NXL
Jun 10, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.447
Real-time Price: $0.358 info
Change: -$0.089 (-20%) info
Market Cap: $7.88M info